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Concomitant intraoperative renal artery
embolization and resection of complex renal
carcinoma
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G. Moore, MD,c and Alan B. Lumsden, MD,a Houston, Tex; and Atlanta, Ga
Background: Renal cell carcinoma, which has the propensity for rapid enlargement and local invasion, may present a
surgical challenge, in part because of extensive vascularity. Conventional treatment typically involves staged preoperative
renal artery embolization followed by nephrectomy after 1 or 2 days. We evaluated the clinical outcome of concomitant
intraoperative embolization and nephrectomy.
Methods: Over 7 years, eight patients with renal cell carcinoma underwent combined intraoperative renal artery coil
embolization and nephrectomy. A cohort of 14 patients who underwent staged renal embolization and nephrectomy
during the same period served as the control group. Renal tumor embolization was achieved via percutaneous femoral
artery approach, followed by coil placement in the distal portion of the main renal artery. Complete renal artery
embolization was confirmed with intraoperative angiography. Nephrectomy was performed either concomitantly or after
renal artery embolization, dependent on treatment group. Intraoperative data, clinical outcome, and hospital cost were
compared between the two groups.
Results: Renal artery embolization and nephrectomy were successfully performed in all patients. There was no perioper-
ative mortality. Mean hospital length of stay in the combined and staged treatment groups was 5.6  1.3 days and 10.2
 3.2 days, respectively. Post-infarction syndrome developed in four patients (36%) in the staged group, compared with
no patients in the combined treatment group. Decreased room cost and radiology cost was noted in the combined
treatment group compared with the staged group. Mean total hospital cost was significantly less in patients who
underwent the combined treatment compared with the staged treatment approach (mean difference, $9214; P  .02)
During mean follow-up of 36 months, six patients (27%) died of unrelated causes. There was no evidence of tumor
recurrence in surviving patients.
Discussion: In patients with renal cell carcinoma, combined renal embolization and nephrectomy minimizes patient
discomfort and post-infarction syndrome associated with traditional staged treatment. Moreover, it is associated with
reduced hospital costs, due in part to decreased hospital length of stay. Vascular surgeons with endovascular skills are well
suited to perform intraoperative renal artery embolization. Use of adjunctive endovascular techniques to facilitate large
open procedures is a growing role for the endovascular-competent vascular surgeon. (J Vasc Surg 2003;38:446-50.)
Renal cell carcinoma has the propensity to enlarge
rapidly and disseminate locally, which frequently results in a
highly vascular tumor with local structural invasion. Pa-
tients with renal cell carcinoma often have gross hematuria,
flank pain, and palpable abdominal mass.1 As many as 20%
of patients with primary renal cell carcinoma have some
degree of tumor thrombus extending into the renal pelvis,
inferior vena cava, and even the hepatic veins.2,3 Although
nephrectomy is the only curative therapy, as well as the
treatment of choice, for primary renal cell carcinoma, sur-
gical treatment can present a daunting challenge, because
of intraoperative hemorrhage associated with excision of
such highly vascular and locally invasive tumors.
In an effort to improve treatment of renal cell carci-
noma, Almgard et al,4 in 1973, proposed transarterial renal
embolization as a means to induce kidney necrosis. Since
then, this has become an accepted form of treatment of
advanced or unresectable renal cell tumors with persistent
bleeding or manifestations of paraneoplastic syndrome.
Moreover, this treatment has become an accepted preop-
erative adjunct to nephrectomy. Although the predomi-
nant benefit of preoperative renal embolization is reduction
of operative blood loss associated with nephrectomy,5 it
also decreases vena cava tumor size and creates an easier
dissection plane as a result of tissue edema.6-9
Preoperative renal embolization to treat renal cell car-
cinoma is typically performed by interventional radiolo-
gists, using intravenous sedation, 1 or 2 days before ne-
phrectomy. Because of renal infarction as a result of
embolization, patients often have severe flank pain and
fever after the procedure.6 In addition, staged treatment
often creates added emotional anxiety for patients and
families.6 We report a combined treatment approach to
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renal cell carcinoma, consisting of intraoperative renal em-
bolization performed by a vascular surgeon and nephrec-
tomy performed by a urologist. The purpose of this study
was to evaluate our experience and the clinical outcome of
combined treatment compared with traditional staged
treatment.
MATERIAL AND METHODS
Eight patients (mean age, 63  5 years) with primary
renal cell carcinoma underwent combined intraoperative
renal artery embolization and nephrectomy between March
1995 and November 2002. Preoperative computed to-
mography (CT) scans of the abdomen demonstrated evi-
dence of tumor extension into the inferior vena cava in two
patients (25%) and retrohepatic vein in two patients (25%).
For purposes of comparison, data for the eight patients
(combined treatment group) were compared with data for
a cohort group of 14 patients (staged treatment group)
with primary renal cell carcinoma who underwent staged
renal artery embolization and nephrectomy during the
study period. Patient demographic data, intraoperative pa-
rameters, and clinical outcome were compared between the
two groups (Table I). Hospital cost data, rather than hos-
pital charges, were assessed by directly obtaining pertinent
information from the hospital accounting department.
Hospital cost for each category of expenditure for the two
groups of patients also was compared (Table II). Statistical
analysis was performed with the Student t test and the
Fisher exact test, with a computer statistical software pro-
gram (SAS Institute, Cary, NC). Test results were consid-
ered significant at P  .05.
For the purpose of cost analysis, four categories of
expenditure encompassing all inpatient hospital costs were
defined, as follows: operating room cost, which included
operating room time, anesthesia time, equipment, operat-
ing room nursing, and recovery room; room cost, which
included regular floor, telemetry bed, and intensive care
unit; radiology cost, which included all diagnostic or ther-
apeutic procedures, such as renal artery embolization, plus
plain radiography, ultrasound scanning, and other diagnos-
tic imaging; other costs, which included pharmacy, trans-
fusion, and laboratory services.
Renal artery embolization. Patients who underwent
combined renal artery embolization and nephrectomy were
placed supine in the operating room, and the renal artery
embolization procedure was performed first. After admin-
istration of general anesthesia via orotracheal intubation,
renal artery embolization was performed by the vascular
surgeon. All embolization procedures were performed with
a 12-inch digital C-arm fluoroscopy unit (Series 9600,
9800; OEC Medical Systems, Salt Lake City, Utah). A
fluoroscopy operating table (Apix; OEC Medical Systems)
was used in all cases. The contralateral femoral artery (op-
posite the renal cell carcinoma) was accessed percutane-
ously, followed by placement of a 7F introducer sheath
(Meditech/Boston Scientific, Natick, Mass). After place-
ment of a pigtail catheter (Meditech) over a 0.035-inch
Bentson guide wire (Meditech), an aortogram was ob-
tained to identify the renal artery feeding the renal cell
carcinoma. A renal double-curve catheter (RDC; Med-
itech) was placed over a 0.035-inch Bentson guide wire to
cannulate the renal artery. Then the double-curve catheter
Table I. Patient demographic data and treatment outcome
Variable
Combined treatment group
(n  8)
Staged treatment group
(n  14) P
Mean age (y) 63  5 68  7 .52
Male gender 6 (75) 11 (79) .48
Mean tumor size (cm) 7.6  1.9 7.9  2.2 .39
Caval tumor involvement 2 (25) 4 (29) .37
Hepatic vein involvement 2 (25) 1 (7) .21
Mean operative blood loss (mL) 320  200 410  260 .38
Mean operative time (min) 260  170 230  190 .59
Mean hospital stay (d) 5.6  1.3 10.2  3.2 .02
Mean ICU stay (d) 0.5  0.6 1.1  0.8 .38
Postinfarction syndrome 0 5 (36) .03
Postoperative renal insufficiency 0 1 (7) .42
Numbers in parentheses are percent.
Table II. Comparison of hospital costs
Mean hospital cost
per patient
Combined treatment group
(n  8)
Staged treatment group
(n  14) P
Operating room $3652  $1525 $3158  $952 .23
Room $4652  $1025 $9832  $1952 .01
Radiology $ 952  $452 $3250  $952 .02
Other $ 865  $336 $1235  $419 .08
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was removed. A 7F multipurpose guiding catheter (Med-
itech) was placed over the Bentson guide wire and posi-
tioned in the proximal renal artery. The double-curve cath-
eter was inserted into the renal artery through the guiding
catheter, and coils (Tornado; Cook, Bloomington, Ind)
ranging in size from 3 to 5 mm were inserted in the distal
portion of the main renal artery. A completion renal angio-
gram was obtained, using the guiding catheter, to demon-
strate total occlusion of the renal artery by the coils. Next
the guiding catheter was removed from the introducer
sheath. The sheath was left in place in the groin during
nephrectomy, and was removed after completion of the
operation.
Nephrectomy. In patients who underwent the com-
bined approach, nephrectomy was performed immediately
after renal embolization. This was accomplished via midline
abdominal incision with retroperitoneal dissection. The
renal vein was first ligated before nephrectomy, to mini-
mize manipulation or propagation of tumor thrombus into
the systemic venous circulation. The renal cell carcinoma,
including the Gerota fascia, was completely excised in all six
patients. Adrenalectomy was performed in one patient in
whom the tumor had extended to the adrenal gland, as seen
on the preoperative abdominal CT scan. All involved lymph
nodes were removed adjacent to the renal hilum or the
aorta. For patients who underwent staged treatment, mean
duration between renal embolization and nephrectomy was
3.3  1.2 days (range, 1-5 days).
All patients received intravenous antibiotic before and
after nephrectomy. Narcotic analgesics with morphine were
provided as needed, in the form of patient-controlled anal-
gesia. Data relating to follow-up visits were evaluated.
Mean follow-up was 36.6 months (range, 5-86 months).
RESULTS
The renal cell tumor was successfully resected in all
patients. Renal artery embolization was also successfully
performed in both the combined and staged treatment
groups. Comparison of clinical variables between the two
groups demonstrated increased length of hospital stay in
the staged treatment group compared with the combined
treatment group (5.6  1.3 days vs 10.2  3.2 days; P 
.02; Table I). Post-infarction syndrome did not develop in
any patients in the combined treatment group, but in four
patients in the staged treatment group (P  .03; Table I).
Operative time in the combined treatment group was
longer than in the staged treatment group, but the differ-
ence did not reach statistical significance (Table I). Intra-
operative autologous red blood cell transfusion was neces-
sary in only one patient (13%) in the combined treatment
group, who received 2 units of blood. There was no peri-
operative mortality in either group. Mean volume of con-
trast medium used in the combined treatment group was
20 mL, compared with 25 mL in the staged treatment
group (difference not significant). Two patients (25%) in
the combined treatment group underwent caval recon-
struction with interposition polytetrafluoroethylene
(PTFE) grafts (W. L. Gore & Associates, Flagstaff, Ariz),
with assistance from a vascular surgeon after caval tumor
thrombectomy. In contrast, concomitant caval reconstruc-
tion was necessary in four patients (29%) in the staged
treatment group. One patient (13%) in the combined treat-
ment group had to return to the operating room for repeat
exploration, because of persistent hypotension and signifi-
cant reduction in postoperative hematocrit. Repeat explo-
ration revealed hemorrhage from a branch of the adrenal
vein that was not adequately suture ligated at the initial
operation. There were no other operative complications in
the remaining patients. No patient in the combined treat-
ment group had postoperative renal dysfunction, defined as
serum creatinine concentration greater than 15% of base-
line. In contrast, one patient (7%) in the staged treatment
group had postoperative renal insufficiency. During fol-
low-up three patients died of myocardial infarction, one
patient died of osteomyelitis 3 years later, and two patients
died of Alzheimer disease. There was no evidence of tumor
recurrence in surviving patients in either group.
Comparison of hospital costs in four categories of
expenditure revealed significantly increased room cost and
radiology cost in the staged treatment group compared
with the combined treatment group (Table II). Although
the combined treatment group had slightly higher operat-
ing room cost and lower cost in the other expenditures
category, these costs were not significantly different com-
pared with those in the staged treatment group. Last, mean
total hospital cost was significantly lower in the combined
treatment group compared with the staged treatment
group (mean cost difference, $9214; P  .02)
DISCUSSION
Renal artery embolization in treatment of renal cell
carcinoma has become widely accepted since it was intro-
duced nearly three decades ago.4 Craven et al9 in 1991
reported its use as a temporizing measure to minimize
operative bleeding or to improve clinical status until de-
layed nephrectomy was performed. Since then, several clin-
ical studies have shown that preoperative renal emboliza-
tion significantly reduces blood loss during nephrectomy,
especially in large hypervascular tumors.5,7,8,10
Renal artery embolization is traditionally performed by
an interventional radiologist. In this percutaneous proce-
dure, the patient undergoes selective catheterization of the
renal artery via the groin, followed by catheter-directed
placement of embolic materials, such as alcohol or coils, to
induce renal tumor infarction. Staged nephrectomy typi-
cally is performed several days later by a urologist. A major
concern with the staged approach is post-infarction syn-
drome, characterized by flank pain lasting 24 to 48 hours,
nausea, vomiting, ileus, fever, and leukocytosis associated
with negative urine and blood cultures.11 The syndrome is
caused by acute infarction of a large parenchymal organ,
and has also been noted after nonrenal embolization, such
as in the spleen.12
Combined intraoperative renal artery embolization and
nephrectomy is a new treatment approach to renal cell
carcinoma. Rather than an interventional radiologist per-
JOURNAL OF VASCULAR SURGERY
September 2003448 Lin et al
forming the initial renal embolization, a vascular surgeon
performs intraoperative renal embolization concomitant
with nephrectomy, performed by a urologist. The catheter-
based skills required to perform intraoperative renal artery
embolization encompass the basic endovascular techniques
that many vascular surgeons routinely use in their practice.
The technical aspect of renal artery catheterization for
embolization mirrors that of renal artery stent placement.
Catheter-directed coil placement in the renal artery is also
similar to hypogastric artery embolization performed in
endovascular aortoiliac aneurysm repair. The mobile C-arm
unit and fluoroscopic operating table used in this procedure
are the identical equipment most vascular surgeons use
when performing endovascular procedures in the operating
room.
The combined treatment approach has several advan-
tages over traditional staged treatment. First, renal artery
embolization and nephrectomy are coordinated by the
vascular surgeon and urologist; thus the patient receives
one general anesthetic for two planned procedures. This
provides the benefit of minimizing the undue emotional
strain and mental anxiety associated with two procedures
performed separately in the radiology suite and operating
room. We previously described our experience of concom-
itant inferior vena cava filter placement in patients under-
going major orthopedic procedures, and noted that pa-
tients experienced less anxiety when two procedures are
performed jointly under the same general anesthetic rather
than performed separately in the radiology suite and oper-
ating room.13 Second, because nephrectomy is performed
immediately after renal embolization, the possibility of
post-infarction syndrome is averted. Patients are not sub-
jected to the physical pain and emotional distress associated
with tumor infarction. Abscess formation or sepsis may
occur after tumor embolization performed before nephrec-
tomy, particularly in patients with indwelling nephrostomy
tubes because of obstructing renal cell carcinoma.14 Weck-
ermann et al11 showed that if nephrectomy is performed
more than 4 days after renal artery embolization, emphyse-
matous pyelonephritis may occur, as evidenced by intrare-
nal gas formation on the abdominal CT scan. In this
circumstance, mortality due to septic complications of
post-infarction syndrome can reach as high as 10%.11 In our
study, post-infarction syndrome did not occur in any pa-
tients in he combined treatment group, compared with
36% of patients in the staged treatment group. Another
advantage of combined treatment is reduced hospital cost.
Our analysis showed a significant reduction in hospital
room cost and radiology cost in the combined treatment
group compared with the staged treatment group (Table
II). The reduction in the room cost was largely related to
decreased hospital length of stay in the combined treatment
group, because patients who underwent staged treatment
waited on average 3.3 days after renal embolization before
undergoing nephrectomy. Last, with more endovascular
procedures being performed in the operating room, such as
aortic endografting and iliac stent placement, vascular sur-
geons are ideally suited to perform renal artery emboliza-
tion. Vascular surgeons are fully capable of handling poten-
tial complications of this percutaneous procedure, such as
groin hematoma and femoral artery dissection. Moreover,
vascular surgeons are often called on to assist with caval
reconstruction after nephrectomy and caval thrombec-
tomy. Coordinating these procedures with the urologist to
facilitate operative treatment of renal cell carcinoma will no
doubt benefit patient care and improve treatment outcome.
Numerous embolic materials have been described in
the literature for use in pre-nephrectomy tumor emboliza-
tion, including ethanol, occluding balloon catheter, and
coils.15-17 Regardless of the thrombotic agent used, these
embolic materials are all effective in achieving complete
renal artery occlusion with tumor infarction. We prefer coil
rather than ethanol, for several reasons. First, the radiolu-
cency of ethanol makes it difficult to visualize the progres-
sion of embolization. The poor visibility of ethanol has
been linked to aortic reflux or injection into nontargeted
arteries. Complications as the result of improper ethanol
injection have included death, left ventricular failure, spinal
cord infarction, and colonic necrosis.18-21 Second, we have
gained considerable experience in coil occlusion, due in
part to our efforts in hypogastric artery embolization in
endovascular treatment of aortoiliac aneurysm.22 When
performing catheter-directed renal artery coil placement, it
is noteworthy that coils must be placed in the distal portion
of the main renal artery to allow adequate length for
proximal renal artery ligation at nephrectomy.15 Serious
complications of improper coil placement, resulting in un-
intentional embolization of nontargeted organs, have sim-
ilarly been reported, and include necrosis of the left colon,
spinal cord, contralateral kidney, and testicular artery, and
lower extremity gangrene.23-26 Bearing these factors in
mind, great care must be taken to ensure that the injection
catheter is placed well within the main renal artery and that
inadvertent coil placement near the renal ostium is averted.
One potential disadvantage of the combined approach
may be related to renal dysfunction associated with contrast
medium administration and nephrectomy. Although no
patients in our series had renal failure after concomitant
renal artery embolization and nephrectomy, we postulate
that such a complication is possible if excessive contrast
medium is administered in a dehydrated patient undergo-
ing nephrectomy. In our series, vigilant efforts were made
to limit the amount of contrast medium used in renal artery
embolization. Furthermore, a central venous catheter was
used perioperatively in all patients to ensure good hydra-
tion to minimize the likelihood of renal dysfunction.
There are several limitations to our study. The number
of patients in this retrospective study is small, and the
duration of follow-up is limited. Moreover the study en-
compassed a group of patients with heterogeneous renal
cell carcinoma. A large-scale prospective study will no
doubt provide further insight regarding the clinical efficacy
of this combined treatment strategy.
In conclusion, our report illustrates the role of an
adjunctive endovascular procedure in facilitating a conven-
tional open operation. Intraoperative renal embolization
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can minimize blood loss and facilitate nephrectomy when
performed jointly with a urologist. Moreover, we believe
this approach minimizes post-infarction syndrome and re-
duces hospital cost, compared with the traditional staged
treatment approach. Additional clinical studies will be nec-
essary to further validate the benefit of combined treatment
in patients with renal cell carcinoma.
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